Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

169.37 +0.59 (+0.35%)
Streaming Delayed Price Updated: 10:13 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock ↗
Via Stocktwits
News headline image
Why This Fund Cashed Out of a $3.6 Million Biotech ETF Bet ↗
After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗
Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings. 
Via Stocktwits
Topics Artificial Intelligence Stocks
News headline image
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗
Via MarketBeat
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗
Via Stocktwits
CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit ↗
Via Stocktwits
CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back ↗
Via Stocktwits
News headline image
Clean Energy’s Second Wind: What iShares Global Clean Energy ETF Tells Us Now ↗
Clean Energy’s Second Wind: What iShares Global Clean Energy ETF Tells Us Now 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals ↗
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗
Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025. 
Via Benzinga
Topics ETFs
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
News headline image
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
News headline image
Enpro Moves To Boost Profits With $280 Million Acquisition Push ↗
Enpro Inc. (NYSE: NPO) acquiring AlpHa Measurement Solutions and Overlook Industries for $280 million in cash. 
Via Benzinga
News headline image
Financial Markets Signal Near 100% Probability of Fed Rate Cut: What it Means for the Economy and Investors
The financial markets are currently flashing a near 100% probability of a Federal Reserve interest rate cut at the upcoming October 28-29 Federal Open Market Committee (FOMC) meeting. This overwhelming... 
Via MarketMinute
Topics Bonds Credit Cards Economy
News headline image
Destiny Wealth Sells $8.1 Million in IBB Shares — Here’s Why Biotech Stocks Are Lagging ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Regulatory Compliance
News headline image
How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline ↗
Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on. 
Via Benzinga
Topics ETFs Government
News headline image
SciSparc And AutoMax Call Off Merger ↗
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
News headline image
Dallas Fed President Lorie Logan Warns Against Premature Rate Cuts, Prioritizing Inflation Fight
Federal Reserve Bank of Dallas President Lorie Logan delivered a stark warning on October 2nd and reiterated it today, October 3rd, 2025, emphasizing the paramount importance of tackling persistent... 
Via MarketMinute
Topics Bonds Credit Cards Economy
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Small Cap Revival: Could Rate Cuts Spark a Rebound in Smaller Companies?
As whispers of impending interest rate cuts grow louder from central banks worldwide, a new wave of optimism is beginning to ripple through the often-overlooked small-cap sector. These nimble,... 
Via MarketMinute
Topics Economy
News headline image
Biotech Sector May Flip to Market Leader by Year-End ↗
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter. 
Via MarketBeat
Topics ETFs Economy Stocks
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market ↗
The FDA had already been investigating two earlier deaths linked to Elevidys. 
Via Stocktwits
Topics Death
News headline image
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn ↗
President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs ↗
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
News headline image
US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care ↗
The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients. 
Via Stocktwits
Topics Government Lawsuit Religion
News headline image
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
News headline image
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns ↗
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
News headline image
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
The Major Sector ETFs Got Their Story ↗
XRT has more work to do. At best, the consumer sector is trying to bottom. At worst, this is a rally into resistance. 
Via Talk Markets
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.